Cognition in The Blood (Biomarker) How do digital cognitive assessments relate to the Blood Plasma p-Tau217 in patients with Mild Cognitive Impairment (MCI)? Our latest research explores an exciting dataset with the AI–Mind Project, who have given us the opportunity to test the associations of our cognitive assessments alongside classic paper-and-pencil tests to levels of […] The post Cognition in The Blood (Biomarker) appeared first on Cambridge Cognition.| Cambridge Cognition
AAIC25 | Posters & Presentations Toronto, Canada | 27th – 31st July | Booth 1531 Unveiling Cutting-Edge Alzheimer’s & Dementia Research at AAIC 2025: A Sneak Peek at Our Latest Posters The Alzheimer’s Association International Conference (AAIC) is just around the corner, and we’re incredibly excited to share some of the latest research our team […] The post AAIC25 | Posters & Presentations appeared first on Cambridge Cognition.| Cambridge Cognition
SIRS 2025: Insights on Schizophrenia Research, From Rights Based Care to Digital Biomarkers Michael Spilka, Sr. Clinical Scientist This year’s Schizophrenia International Research Society (SIRS) 2025 Congress in Chicago brought together leading scientists and researchers, exploring the latest advancements and ongoing challenges in understanding and addressing schizophrenia. Michael Spilka, PhD. shares his key insights from […] The post SIRS 2025: Insights on Schizophrenia Research, From R...| Cambridge Cognition
When to Use Standardised Assessments—And When You Might Need to Build Your Own Alex Kaula, Senior R&D Scientist Hello, I’m Alex Kaula, Senior R&D Scientist at Cambridge Cognition. If your research involves measuring cognitive function or clinical outcomes, you’ve likely faced this question: Should I use an established, validated assessment, or create a new one […]| Cambridge Cognition
The post Development and Characterization of Covalent Inhibitors of the RAS-PIK3CA interaction appeared first on Vividion Therapeutics.| Vividion Therapeutics